Newton Charles W.

CIK 00018662195 companiesLEXINGTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001866219

Recent Transactions

36 trades

Award
Keros Therapeutics, Inc.$KROS
Stock Option (Right to Buy)
2026-03-09+14,788→ 14,788 total
Award
Keros Therapeutics, Inc.$KROS
Common Stock
2026-03-09+13,215→ 13,215 total
Sale
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-08-21$10.54/sh−1,453→ 15,306 total
Award
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-08-20+8,000→ 16,759 total
Sale
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-08-12$10.34/sh−136→ 8,759 total
Sale
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-08-11$10.53/sh−131→ 8,895 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2025-06-12+112,000→ 112,000 total
Disposition to Issuer
2seventy bio, Inc.
Stock Options (Right to buy)
2025-05-13−12,050→ 0 total
Disposition to Issuer
2seventy bio, Inc.
Stock Options (Right to buy)
2025-05-13−33,400→ 0 total
Disposition from Tender
2seventy bio, Inc.
Common Stock
2025-05-13−5,533→ 0 total
Disposition to Issuer
2seventy bio, Inc.
Common Stock
2025-05-13−17,092→ 5,533 total
Award
NOVAVAX INC$NVAX
Restricted Stock Units
2025-04-25+28,560→ 28,560 total
Award
NOVAVAX INC$NVAX
Stock Option (Right to buy)
2025-04-25+42,840→ 42,840 total
Purchase
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-03-17$0.56/sh+200,000→ 200,000 total
Award
Lyell Immunopharma, Inc.$LYEL
Option (right to buy)
2025-02-10+450,000→ 450,000 total
Award
Lyell Immunopharma, Inc.$LYEL
Common Stock
2025-02-10+112,500→ 172,725 total
Award
Lyell Immunopharma, Inc.$LYEL
Option (right to buy)
2025-02-10+56,250→ 56,250 total
Award
2seventy bio, Inc.
Common Stock
2024-06-10+6,025→ 22,625 total
Award
2seventy bio, Inc.
Stock Options (Right to buy)
2024-06-10+12,050→ 12,050 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2024-06-03+112,000→ 112,000 total
Award
2seventy bio, Inc.
Common Stock
2024-03-20+16,600→ 16,600 total
Award
2seventy bio, Inc.
Stock Options (Right to buy)
2024-03-20+33,400→ 33,400 total
Award
Lyell Immunopharma, Inc.$LYEL
Common Stock
2024-02-09+40,000→ 48,729 total
Award
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2024-02-09+400,000→ 400,000 total
Disposition to Issuer
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16−190,000→ 0 total
Award
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16+516,000→ 516,000 total
Award
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16+190,000→ 190,000 total
Award
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16+3,612,000→ 3,612,000 total
Disposition to Issuer
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16−516,000→ 0 total
Disposition to Issuer
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16−500,000→ 0 total
Disposition to Issuer
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16−3,612,000→ 0 total
Award
Lyell Immunopharma, Inc.$LYEL
Stock Option (right to buy)
2023-11-16+500,000→ 500,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2023-06-07+38,250→ 38,250 total
Award
Lyell Immunopharma, Inc.$LYEL
Option (right to buy)
2023-02-24+700,000→ 700,000 total
Award
Coherus Oncology, Inc.$CHRS
Stock Option (Right to Buy)
2022-05-04+54,000→ 54,000 total
Award
Lyell Immunopharma, Inc.$LYEL
Option (right to buy)
2022-03-16+500,000→ 500,000 total

Companies

Recent Filings

Address

C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302

LEXINGTON, MA, 02421

View on SEC.gov